Research and Development

Olainfarm Invests Nearly 2 Million Euro to Modernise the Phenibut Intermediate Unit

on 11 rugsėjo, 2015 Komentavimas išjungtas įraše Olainfarm Invests Nearly 2 Million Euro to Modernise the Phenibut Intermediate Unit

JSC Olainfarm has completed the modernisation of the phenibut semi-product unit, where the semi-product is manufactured for the active pharmaceutical substance for medicines improving the function of the central nervous system. The unit underwent simplified renovations, and equipment has been purchased and installed to allow doubling the phenibut production volumes. Within the project, the production of new finished drug forms „Noofen 100” has been commenced. This has been implemented with the support of the European Regional Development Fund.

„As we were approaching the 40-year anniversary of Olainfarm in 2012, we informed of our plans to invest about 50 million euro in production development within the upcoming decade. Modernisation of the phenibut intermediate unit is one of such high added value investment and development projects. Before then, we had already established a nitrofuran drug production unit, and we are currently working on the modernisation of a mebicar production unit, establishment of a production plant of anti-tuberculosis active pharmaceutical substance, modernisation and expansion of the packaging process and finished product warehouses,” adds the member of the Board of JSC Olainfarm Salvis Lapiņš.

Olainfarm_fenibuta_pusproduktu_iecirknis_1

Sales volumes of the original product of JSC Olainfarm — „Noofen” — with the active pharmaceutical substance phenibut, have doubled over the last five years. It is one of the top sellers of JSC Olainfarm products.

The phenibut intermediate unit covers an area of 965 sq. metres in the 4th and 6th production block of JSC Olainfarm. It is undergoing repairs, and production equipment is being purchased and installed, including quality control equipment and modern, high performance liquid chromatographs with mass detectors of new structure. They not only allow to control the admixture contents in the analysed sample, but also to identify the molecular structure of admixtures. Production at the new unit will be carried out in compliance with the requirements of Good manufacturing practice and ISO 14001 standards.

The total project costs are 1.9 million euro, of which 0.2 million euro is the requested funding from the European Regional Development Fund. Of the total project investments, 1 million was invested in reconstruction works, whereas 0.9 million, in production and quality control equipment.

The unit was modernised within the third phase project „Modernisation of the phenibut intermediate unit” within the activity 2.1.2.4 „High added value investments” of the extension to the programme „Entrepreneurship and innovation”, on which JSC Olainfarm concluded an Agreement No. L-APV-14-0069 on 25 March 2014 with the Latvian Investment and Development Agency.

 

eraf

 

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Further information:

Sigita Lapsiņa
Head of PR
Cell: +371 2 6377286
E-mail: slapsina@olainfarm.lv

 

read more
Olainfarm Invests Nearly 2 Million Euro to Modernise the Phenibut Intermediate Unit

In co-operation with the Latvian Institute of Organic Synthesis, Olainfarm performs pharmacological studies and develops a technology for the production of three new active pharmaceutical substances

on 9 rugsėjo, 2015 Komentavimas išjungtas įraše In co-operation with the Latvian Institute of Organic Synthesis, Olainfarm performs pharmacological studies and develops a technology for the production of three new active pharmaceutical substances

In co-operation with the Latvian Institute of Organic Synthesis (LIOS), JSC Olainfarm has developed a technology for the synthesis of three new active pharmaceutical substances for cost-efficient production in industrial quantities. Studies have been performed at the project pharmacology unit, which will allow JSC Olainfarm to develop new medicines for the treatment of neurodegenerative illnesses. Several inventions achieved during the project are patented. The total project costs amount to 0.57 million EUR, and it is implemented with the support of the European Regional Development Fund.

„Knowledge and intellectual property rights gained during the project will allow JSC Olainfarm to develop new drugs to expand the company’s product portfolio, to increase competitiveness and exportability. In the future, it will give a positive contribution to Latvian and European Union economies alike,” adds Vilnis Liepiņš, Head of R&D of APIs and Intermediates at JSC Olainfarm.

The project consists of a technology development and a pharmacology section. Thus, in the technological section, most cost-efficient and best ways of synthesis are found and technological parameters are optimised to allow obtaining the necessary active pharmaceutical substances according to the high quality requirements of our time. In co-operation with LIOS scientists, unique ways of synthesis have been discovered, which are now protected in capacity of industrial intellectual property after applying for a Latvian or international patent.

In the pharmacology section of the project, several active pharmaceutical substances have been studied in vivo, and their potential use for new therapeutic indications has been discovered. One of the products is showing very good prospects for neuropathic pain treatment properties. This discovery is very important and it has patentability, which means that JSC Olainfarm will be able to protect it as intellectual property and will be able to develop a new product on its basis for treating neurodegenerative illnesses. Another product demonstrated potential anti-inflammatory effect, related to reducing the inflammation factor secretion. The rights to the intellectual property generated as a result of this study are corroborated with an international patent application No. PCT/IB2015/053554. Post-stroke neuro-regenerative properties, analgesic properties and mechanisms of functioning of one active pharmaceutical substance were also studied within the project. The results of these studies have been presented in two scientific articles in international peer-reviewed pharmacology journals.

Studies have been performed within the project „Development of methods of synthesis of active pharmaceutical substances and study of pharmacological profile”, on which JSC Olainfarm concluded an Agreement No. 2013/0030/2DP/2.1.1.1.0/13/APIA/VIAA/001 on 2 December 2013 with the State Education Development Agency. Of the total project costs of 0.57 million EUR, 0.29 million EUR is co-financed by the European Regional Development Fund.

 

eraf

 

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Further information:

Sigita Lapsiņa
Head of PR
Cell: +371 2 6377286
E-mail: slapsina@olainfarm.lv

read more
In co-operation with the Latvian Institute of Organic Synthesis, Olainfarm performs pharmacological studies and develops a technology for the production of three new active pharmaceutical substances

Olainfarm Invests 9.6 Million Euros in New Final Dosage Form Production Unit

on 13 sausio, 2015 Komentavimas išjungtas įraše Olainfarm Invests 9.6 Million Euros in New Final Dosage Form Production Unit

Today with participation of President of Latvia Andris Berzins, the new final dosage form production unit of JSC Olainfarm was opened. The unit includes final dosage form site for nitrofuranes, small batch production unit and final dosage development laboratory.  The project has been implemented with a support from European Regional Development Fund.

„Olainfarm has always been the most outstanding locomotive of Latvian chemical industry, which today, with opening of the capacities is doubling our economic capabilities.  Because of skilful management and introduction of new technologies, the company has been able to find markets in new and distant countries,” says President of Latvia Andris Berzins.

The new production unit has been built through reconstruction of previously underused building.  Its total space is 2112 square metres.  The building has two floors and is connected to the main final dosage form production unit. On the ground floor there is a small batch production unit and final dosage development laboratory, but on the second floor the nitrofurane final dosage production unit and in-process quality control laboratories are located.

„New final dosage form production unit of Olainfarm is a high added value investment project, that will help company to strengthen its competitiveness in growing world market of nitrofuranes and will significantly improve company’s ability to develop new products.  We have a long term experience in production of nitrofuranes, we are the only producer of them in Latvia and the Baltic States and the only ones in former Soviet Union who produce active pharmaceutical ingredients of nitrofuranes. Nitrofuranes make up more than 20% of sales of Olainfarm and during the last five years sales of nitrofuranes have tripled,” adds Chairman of the Board of JSC Olainfarm Mr. Valerijs Maligins.

Antibacterial nitrofurane derivatives, namely Furamag, Furagin, Furadonin and Furasol will be produced in the modernized facility, and after the completion of development process they will be joined by the new nitrofurane product. New equipment will significantly improve the efficiency of production processes, making them highly technological, and at the same time reduce energy consumption.

Small batch final dosage form production unit of JSC Olainfarm will produce smaller batches of finished products and will be used for technology scale-up. Small scale technologies will also allow optimisation of the use of more productive equipment. Final dosage form development laboratory has also been moved to the new building, where it will continue working on new forms of existing products and on development of brand new products.

New final dosage production unit of JSC Olainfarm  is the biggest financial investment in development of pharmaceutical production in the Baltics in 2014.  Total costs of the project are 9.6 million euro, of which 2.5 million euro is funded by European Regional Development Fund. Of the total project costs 4.1 million euro were invested in construction works, 4.8 in production equipment and 0.6 in analytical equipment.

New final dosage form production unit was constructed within the project „High Added Value Investments into Production of Nitrofuranes”, on which the contract No.L-APV-12-0039 was signed between JSC Olainfarm and Latvian Investment and Development Agency on August 15, 2012.

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

Information prepared by:

Salvis Lapins
Member of the Board
JSC Olainfarm
Tel: +371 6 7013 717
Cell: +371 2 6448 873
E-mail: slapinsh@olainfarm.lv

read more
Olainfarm Invests 9.6 Million Euros in New Final Dosage Form Production Unit

Olainfarm Acquires Controlling Stake in Silvanols

on 4 birželio, 2013 Komentavimas išjungtas įraše Olainfarm Acquires Controlling Stake in Silvanols

JSC Olainfarm has acquired 23.37% more shares in Latvian pharmaceutical company Silvanols Ltd., therefore Olainfarm now holds controlling interest in Silvanols. Before that JSC Olainfarm already owned 47.51% of the company’s shares.

„Acquisition of Silvanols is one of the ways for Olainfarm to further consolidate its positions and expand the production of medications. We see a good opportunity to increase the speed of growth by merging expertise, experience and export potential of the two companies and by creating and developing joint projects,” says Salvis Lapiņš, a member of JSC Olainfarm board.

JSC Olainfarm currently owns 70.88% of the company’s shares, Silvanols co-owner Ieva Leimane – 15.41%, Agris Auce – 10.39%, and Sandra Ivanova – 3.31% of  Silvanols Ltd. shares.

Sales of Silvanols Ltd. in 2012 were 1.993 million lats and the company made a net profit of 136 thousand lats.

Consolidated profit and loss statement of JSC Olainfarm for 2012 shows that the concern has set yet another profit record as it has made a net profit of 9.75 million lats (13.88 milion euro).  This represents an increase by 41% compared to 2011, when profit of  JSC Olainfarm was 6.91 million lats (9.84 million euro).

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

Silvanols Ltd. is one of the most rapidly growing Latvian producers of medicines. In its operations Silvanols uses modern internationally applied technologies. Products portfolio of the company consists of unique set of original products, including over-the-counter medicines, medical devices and food supplements, in total more than 70 different original products. Company is particularly proud of their original products, including market leader Faringo Spray®, anti-rhinitis gel Rinogēls® and sedative mixture of 7 different herbs  Relaxen®. Currently products of the company are being exported to Lithuania, Estonia, Azerbaijan, Romania, Czech Republic, Hungary, Belarus, Kazakhstan, Slovakia and Armenia.

 

Information prepared by:

Salvis Lapins
Member of the Board
JSC Olainfarm
Tel: +371 6 7013 717
Cell: +371 2 6448 873
E-mail: slapinsh@olainfarm.lv

 

read more
Olainfarm Acquires Controlling Stake in Silvanols

Olainfarm to Receive Corporate Income Tax Exemption for 5.21 Million Lats

on 7 gegužės, 2013 Komentavimas išjungtas įraše Olainfarm to Receive Corporate Income Tax Exemption for 5.21 Million Lats

JSC Olainfarm will be given corporate income tax exemption for approved long term investments made within the project “Introduction of new products and improved exporting capacity”. This decision was made on the meeting of Cabinet of Ministers held on May 7, and was based on assessment done by the Ministry of Economy about impact such exemption would have on national economy and local competition.  It is planned that the total tax exemption could be as high as 5.21 million lats.

“We are glad about such decision our government has made to provide this tax exemption to Olainfarm.  It is a very significant support for us to introduce new products and further develop our sales markets,” says Salvis Lapins, Member of the Board of JSC Olainfarm.

The project “Introduction of new products and improved exporting capacity” provides that JSC Olainfarm will introduce several new products and will significantly adjust several production processes and increase production efficiency. In total, within this project JSC Olainfarm will invest 22.95 million lats over the course of five years. Tax exemption will be applicable upon completion of the project.

Part of the investments that JSC Olainfarm will make within this project (5.29 million lats) will be merged with co-funding of European Regional Development Fund approved by Latvian Investment and Development Agency as part of “High Added Value Investments „.

As regulations of both support programmes allow combining tax exemptions with funding approved as part of other programmes and with the respective eligible costs, investmets worth 5.29 million lats supported by LIDA and ERDF are also included in the support programme adopted by the Cabinet.

Since intensity of the support in LIDA’s project approved for JSC Olainfarm is 35% of totas eligible costs and since company qualifies as big commercial company, a tax exemption of 15% will be applied for investments made from project approved by LIDA, while the rate of 25% is applicable to other investments worth 17.65 million lats.

 

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Information prepared by:

Salvis Lapins
Member of the Board
JSC Olainfarm
Tel: +371 6 7013 717
Cell: +371 2 6448 873
E-mail: slapinsh@olainfarm.lv

 

read more
Olainfarm to Receive Corporate Income Tax Exemption for 5.21 Million Lats

Olainfarm has Acquired 47.5% of Shares in Silvanols

on 2 gegužės, 2013 Komentavimas išjungtas įraše Olainfarm has Acquired 47.5% of Shares in Silvanols

JSC Olainfarm has acquired 47.5% shares in the third largest Latvian pharmaceutical manufacturer Silvanols Ltd.  It is expected that another 20% or more will be acquired in the nearest future. This acquisition will allow both companies to expand their product groups and portfolio and enter and expand into new markets.

“Over last several years Olainfarm has made significant investments in expansion of its product portfolio, sales markets and business segments. Acquisition of Silvanols is yet another step towards vision of Olainfarm to become a leading producer of finished dosage forms and chemical products in the Baltics, whose products is well known and available throughout the world.  We see a very good opportunity to increase the speed of growth by merging expertise, experience and export potential of the two companies and by creating and developing joint projects,” says Salvis Lapins, Member of the Board of JSC Olainfarm.

Co-owner and the Board Member of Silvanols Ltd. Ieva Leimane notes that this is a logical next step in company’s development.  Having a new shareholder in Silvanols will help the company to develop faster, improve its logistical systems, and, what is particularly important, will provide new export markets for the company. I am sure and our recent experience confirms it, that our products are veru compatitive not only in Latvia but also abroad.”

Chairman of the Board of Silvanols Ltd. Viesturs Gurtlavs emphasizes that “changes that have occurred to list of company’s shareholders will facilitate inflow of new knowledge and experience into Silvanols which will be yet another boost for competitiveness of the company internationally and domestically”.

After the transaction Board Member of Olainfarm Mr. Salvis Lapins has also become a Member of Silvanols’ Board.

Sales of Silvanols Ltd. in 2012 were 1.993 million lats and the company made a net profit of 136 thousand lats.

Consolidated profit and loss statement of JSC Olainfarm for 2012 shows that the concern has set yet another profit record as it has made a net profit of 9.75 million lats (13.88 milion euro).  This represents an increase by 41% compared to 2011, when profit of JSC Olainfarm was 6.91 million lats (9.84 million euro).

 

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Silvanols Ltd. is one of the most rapidly growing Latvian producers of medicines. In its operations Silvanols uses modern internationally applied technologies. Products portfolio of the company consists of unique set of original products, including over-the-counter medicines, medical devices and food supplements, in total more than 70 different original products. Company is particularly proud of their original products, including market leader Faringo Spray®, anti-rhinitis gel Rinogēls® and sedative mixture of 7 different herbs  Relaxen®. Currently products of the company are being exported to Lithuania, Estonia, Azerbaijan, Romania, Czech Republic, Hungary, Belarus, Kazakhstan, Slovakia and Armenia.

 

Information prepared by:

Salvis Lapins
Member of the Board
JSC Olainfarm
Tel: +371 6 7013 717
Cell: +371 2 6448 873
E-mail: slapinsh@olainfarm.lv

read more
Olainfarm has Acquired 47.5% of Shares in Silvanols

Olainfarm to extend the chain of Latvijas Aptiekas

on 13 kovo, 2013 Komentavimas išjungtas įraše Olainfarm to extend the chain of Latvijas Aptiekas

During February of this year JSC Olainfarm agreed with JSC SEB Banka to increase its loan by 6.6 million euros to 12 million euros. It is planned that proceeds from the loan are used to purchase pharmacies and other companies related to pharmaceutical business.  The loan will be due on May, 2015.

„In order to keep the momentum and maintain the long term growth of the company, we will continue with expansion of chain of Latvijas Aptiekas. We are considering the purchase of five new pharmacies which will bring the total number of our pharmacies close to 50 all over Latvia,” says Salvis Lapins, Member of the Board of JSC Olainfarm.

Because of the increase in loan, several new commercial pledge and mortgage loans were signed. According to them the maximum combined amount of secured claim is slightly above 13 million lats. Just as with previous amount of loan, shares in daughter companies of JSC Olainfarm, real estate and other property is pledged.

Consolidated profit and loss account of JSC Olainfarm for operations of 2012 shows that the company has achieved new record profit of 9.75 million lats (13.88 million euros), which is an increase by 41% compared to 2011, when profit of JSC Olainfarm was 6.91 million lats (9.84 million euros).

 

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Information prepared by:

Salvis Lapins
Member of the Board
JSC Olainfarm
Tel: +371 6 7013 717
Cell: +371 2 6448 873
E-mail: slapinsh@olainfarm.lv

read more
Olainfarm to extend the chain of Latvijas Aptiekas

Olainfarm Celebrates 40th Anniversary, Plans to Invest About 35 Million Lats over the Coming decade

on 15 spalio, 2012 Komentavimas išjungtas įraše Olainfarm Celebrates 40th Anniversary, Plans to Invest About 35 Million Lats over the Coming decade

On October 12, JSC Olainfarm celebrated 40 years since first batch of furaginum was synthesized, which marked the beginning of company’s operations.  During the celebrations Chairman of the Boards Mr. Valerijs Maligins not only had reviewed the major achievements, but also came up with forecasts regarding the expected development during the next decade; the company plans to invest about 35 million lats and maintain the growth of about 10-15% per annum, which, if more favourable scenario develops, could be even as high as 20-30%.

„Olainfarm” faces its 40th anniversary in a very good shape – we have gained some experience, increased the production output, entered some new markets and have extended out product portfolio.  Basically we are very well prepared for stable growth and further expansion to new markets in coming years.  This gives me a reason to forecast that during the next decade, with the pessimistic scenario our growth will be at the level of 10-15%.  However, Olainfarm has all the necessary resources to maintain its growth level at about 20-25% or even 30% per annum.  Besides, we do not only grow on our own, we grow in cooperation with local and international partners and with the World Health Organisation,” says Valerijs Maligins, Chairman of Olainfarm’s Board.

V. Maligins emphasizes: „The most important factor influencing development of Olainfarm over the last 40 years and expected to influence it further are people: our employees, scientists, partners, patients. I would like to thank them and wish them further growth together with Olainfarm.”

 

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Information prepared by:

Salvis Lapins
Member of the Board
JSC Olainfarm
Tel: +371 6 7013 717
Cell: +371 2 6448 873
E-mail: slapinsh@olainfarm.lv

read more
Olainfarm Celebrates 40th Anniversary, Plans to Invest About 35 Million Lats over the Coming decade

Olainfarm Plans to Increase Dividends, Strengthens its Product Portfolio in Export Markets

on 13 gegužės, 2012 Komentavimas išjungtas įraše Olainfarm Plans to Increase Dividends, Strengthens its Product Portfolio in Export Markets

JSC Olainfarm is currently finishing registration of capsules of “Noofen” in Russia, plans to start selling capsules of “Olvazol” in Ukraine in September and has started the registration of “Neiromidin” in China, Chairman of the Board Mr Valerijs Maligins told in his interview to portal naudaslietas.lv. JSC Olainfarm plans to gradually increase share of profit payable in dividends, so that in more distant future it might be as high as 90% of profit.

“More significant growth in the future could be achieved if we through share issues purchase new companies,” says Valerijs Maligins, Chairman of the Board of JSC Olainfarm. “In order to keep all financial options open, Olainfarm has to be attractive for investors, therefore we will gradually increase the portion of profit to be paid in dividends.”

At the moment most of company’s profit is being reinvested into the company, for instance, soon the cogeneration project will commence. Possibility of purchasing other producers of pharmaceuticals, herbal medicines or elastic bandages is also not ruled out.

Currently JSC Olainfarm is finishing the registration of capsules of “Noofen” in Russia. According to company’s forecasts, in 5-6 years volume of sales of “Noofen” to Russia could reach 6 million euros.

Sales forecasts of JSC Olainfarm for 2012 provides that unconsolidated sales will reach 40 million lats (56.9 million euros), but consolidated sales will be as high as 47 million lats (66.9 million euro).

 

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Information prepared by:

Salvis Lapins
Member of the Board
JSC Olainfarm
Tel: +371 6 7013 717
Cell: +371 2 6448 873
E-mail: slapinsh@olainfarm.lv

 

read more
Olainfarm Plans to Increase Dividends, Strengthens its Product Portfolio in Export Markets

Minister of Health Ingrida Circene Visits Olainfarm

on 29 vasario, 2012 Komentavimas išjungtas įraše Minister of Health Ingrida Circene Visits Olainfarm

Today, on February 29, 2012, JSC Olainfarm was visited by Minister of Health Ingrida Circene and together with Chairman of Olainfarm’s Board Mr. Valerijs Maligins opened an extended Centre of Chromatography. Minister also visited the unit of final dosage forms and saw other recent improvements in the company.

“Olainfarm has proven that with effective and high quality operations one can achieve stable economic development, despite any financial crises. This is also a good example for other Latvian companies,” Ingrida Circene shared her impressions.

V.Maligins_I.Circene_atklasana

 

Centre of Chromatography is a structural unit of Quality Management department, conducting analytical testing with methods or instrumental chromatography, developing and validating new testing methods. It also performs chromatographic analyses, quality control of medicines, active pharmaceutical ingredients and chemical products, both for finished and in progress products.

Centre of Chromatography was initially opened in January of 2007. In order to increase its capacity, at the end of 2011 extension of premised took place and new laboratory furniture and equipment was purchased. This modernisation resulted in doubling of space and creation of 12 new workplaces. New equipment will increase productivity of laboratory and its capacity for scientific work and introduction of new medicines.

 

JSC Olainfarm is one of the biggest pharmaceutical companies in Latvia with more than 40 years of experience in production of medication and chemical and pharmaceutical products. A basic principle of company’s operations is to produce reliable and effective top quality products for Latvia and the rest of the world. Products made by the Group are being exported to more than 35 countries of the world, including the Baltics, Russia, other CIS, Europe, Asia, North America and Australia.

 

Information prepared by:

Salvis Lapins
Member of the Board
JSC Olainfarm
Tel: +371 6 7013 717
Cell: +371 2 6448 873
E-mail: slapinsh@olainfarm.lv

read more
Minister of Health Ingrida Circene Visits Olainfarm

Search

Recent Posts